Edwards Lifesciences stock jumped late Thursday after the medtech company boosted its 2025 outlook after beating quarterly ...

Edwards Lifesciences (NYSE: EW) today announced new data demonstrating long-term benefits with its Sapien heart valve system.

WASHINGTON, DC — New European registry data on transcatheter aortic-valve replacement (TAVR) in patients at lower surgical risk than those studied in the pivotal randomized trials offers the ...

Trials from Edwards, Philips and Penumbra were among the most-watched studies at the annual cardiovascular meeting.

The respective readouts demonstrated TAVR’s comparable performance to surgical aortic valve replacement treatment.

SBRT is noninferior to traditional radiation for low- to intermediate-risk localized prostate cancer, offering a viable treatment alternative. The PACE-B study showed a 95.8% five-year rate of no ...

Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced the publication of two studies demonstrating the Afirma GRID (Genomic Resource for Intelligent Discovery) research ...

Edwards’ Q3 revenues were chiefly driven by a 12.4% uplift in its transcatheter aortic valve replacement (TAVR) product group ...

Growing evidence indicates that more patients with favorable Grade Group 2 prostate cancer can be successfully managed with active surveillance and achieve acceptable oncologic outcomes, even if later ...

ORLANDO ‑- Cataract surgery was linked to an increased risk of conversion from dry to neovascular (wet) age-related macular ...